IUB SEAD RED (Revolutionary Endometrial Ablation Device Study

Launched by OCON MEDICAL LTD. · Jul 8, 2021

Keywords

ClinConnect Summary

The IUB SEAD RED clinical trial is studying a new device called the IUB SEAD™ that aims to help women with heavy menstrual bleeding (HMB) caused by non-serious conditions. HMB can lead to health issues like iron deficiency and anemia, and this trial is looking at whether this innovative device can provide a simpler and effective treatment option compared to current methods. This study is being conducted in an office setting, making it more convenient for patients and potentially reducing the need for more invasive procedures like hysterectomy.

To participate in the trial, women aged 40 to 50 who experience heavy menstrual bleeding and meet certain health criteria may be eligible. Key requirements include having a specific level of menstrual blood loss, a normal endometrial cavity, and no recent surgeries affecting the uterus. Participants can expect to undergo a treatment with the IUB SEAD device and will be closely monitored throughout the study. It's important to note that women who are pregnant or trying to conceive, or those with certain medical conditions, may not qualify for the trial. Overall, this study aims to provide a promising new option for women suffering from heavy menstrual bleeding.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Female subject age 40 to 50 years, inclusive
• • 2. Suffering from the symptom of heavy menstrual bleeding (HMB) from benign causes with no definable organic cause and are candidates for endometrial ablation or surgical treatment.
• • 3. PBAC score of \>150 - an average of 2 consecutive screening scores prior to study treatment
• • 4. Are thought to be ovulatory with cyclic predictable onset of menses with a cycle length of 24-38 days.
• • 5. Have either a normal appearing endometrial cavity as assessed by hysteroscopy performed within 90 days of study treatment, or one that is distorted by a FIGO Type 2 submucous leiomyoma ≤3 cm in mean diameter.
• • 6. Have endometrial sampling with normal histology within 6 months of the study procedure.
• • 7. Premenopausal status confirmed by FSH level measurement at screening (FSH \< 40 IU/L). FSH level measurement will be repeated in case of a borderline result
• • 8. Screening hemoglobin levels \>9.0 g/dL
• • 9. Uterine sound measurement of 6.5-12 cm (external os to internal fundus)
• • 10. Negative serum pregnancy test at the Screening visit and on the day of SEAD™ treatment
• 11. women whose sexual activity places them at risk for pregnancy must agree to use an effective, non-hormonal, non-intrauterine method of contraception throughout the course of the study. For this study, acceptable effective methods of contraception are considered to be those listed below:
• • Barrier method, i.e., (a) condom (male or female) with spermicide or (b) diaphragm with spermicide or
• • Vasectomy (partner), or
• • Abstinence, if in line with the preferred and usual lifestyle of the subject \[where abstinence is defined as refraining from heterosexual intercourse\]
• • 12. Subject is able to understand and sign a written informed consent form
• • 13. Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
• • 14. The subject demonstrates an understanding of how to record menstrual blood loss using a menstrual pictogram
• Exclusion Criteria:
• • 1. Pregnant women or those who desire to conceive at any time in the future
• • 2. An endometrial cavity with any of the following: congenital malformation of (eg septate uterus), endometrial polyp \>8 mm in largest dimension, FIGO Type 0 or 1 leiomyomas of any diameter or Type 2 leiomyomas \> 3 cm in mean diameter; intrauterine adhesions/ synechiae that distort the endometrial cavity sufficient to impair deployment of the SEAD device.
• • 3. Underwent prior uterine surgery that interrupts the integrity of the uterine wall (e.g., transmural abdominal (laparoscopic or laparotomic) or hysteroscopic myomectomy and/or metroplasty during last 3 months prior to screening, classical Cesarean section, or endometrial ablation
• • 4. Have an abnormal endometrial biopsy that suggests either anovulation or a risk for the development of endometrial cancer (i.e., benign hyperplasia, endometrial hyperplasia with atypia, endometrial intraepithelial neoplasia, endometrial cancer)
• • 5. Have a documented clinical history of titanium allergy or hypersensitivity
• • 6. Suffers from active endometritis, active pelvic inflammatory disease (PID) or active sexually transmitted disease (STD)
• • 7. Suffers from active infection of the genitals, vagina, cervix, or uterus
• • 8. Presence of bacteremia, sepsis, or other active systemic infection
• • 9. Known/suspected abdominal, pelvic, or gynecological malignancy within the past 5 years
• • 10. Known clotting defects or bleeding disorders
• • 11. Currently using anticoagulant treatment
• • 12. Subjects with abnormal Papanicolaou (Pap) test or atypical squamous cells of undetermined significance (ASCUS) with positive high-risk human papilloma virus (HPV) test result within the appropriate screen timeframe, and prior to SEAD™ treatment. Alternatively, a colposcopy performed prior to SEAD™ treatment, that showed evidence of dysplasia requiring treatment. In case treatment was performed \> 6 months prior to enrollment and follow-up was done with no evidence of disease by clinical evaluation, the subject is eligible.
• • 13. Suffers from clinically significant adenomyosis indicated by subject complaints or imaging
• • 14. Presence of an implantable contraceptive device, unless subject agrees to have the device removed immediately on screening, and prior to PBLAC assessment
• • 15. Post-partum ≤ 6-months
• • 16. Currently participating in or considering participation in a research study of an investigational drug or device that would begin during the course of this investigational study
• • 17. Any general health or mental, or other situation or condition which, in the opinion of the Investigator, could present an increased risk for the subject or impact the subject's ability to comply with protocol requirements.
• • 18. Has a polyp that was not removed before day of treatment
• • 19. Has a BMI\>35